HCC-78 Xenograft Model Service for NSCLC

The HCC-78 xenograft model represents a robust preclinical platform for evaluating ROS1 fusion-targeted therapies in non-small cell lung cancer (NSCLC), leveraging a well-characterized cell line with established molecular drivers and reproducible tumorigenicity. Alfa Cytology provides comprehensive HCC-78 xenograft model services designed to accelerate your preclinical drug development pipeline, offering validated tumor growth kinetics, standardized endpoint analyses, and customizable study designs tailored to ROS1 inhibitor screening and combination therapy evaluation.

Overview of HCC-78 Xenograft Model for NSCLC

The HCC-78 cell line was established from the pleural effusion of a 65-year-old male patient diagnosed with lung adenocarcinoma, specifically classified as mucinous bronchioloalveolar carcinoma, a subtype of NSCLC. This cell line is genetically defined by a SLC34A2-ROS1 chromosomal rearrangement, which produces a constitutively active fusion kinase that drives oncogenic signaling through the MAPK, PI3K-AKT, and JAK-STAT pathways. Additionally, HCC-78 harbors a TP53 S241F inactivating mutation, making it a representative model for concomitant TP53-mutant ROS1-positive NSCLC, a molecular subclass associated with more aggressive disease progression and poorer therapeutic outcomes. The cell line exhibits epithelial-like morphology, adherent growth properties, and a doubling time of approximately 60–70 hours under standard culture conditions.

Fig 1. lncRNA-UCA1 effects on HCC78 cells proliferation and apoptosis. (Tang, Li, et al., 2023)

When implanted into immunocompromised hosts such as athymic nude mice, HCC-78 cells form reproducible subcutaneous tumors that retain the molecular characteristics of the parental cell line, including ROS1 fusion expression and TP53 mutation status. The resulting xenograft model has been extensively validated for preclinical assessment of ROS1-targeted tyrosine kinase inhibitors (TKIs), including crizotinib, entrectinib, and lorlatinib, as well as for studying resistance mechanisms involving EGFR pathway activation, KRAS amplification, and FGFR3 upregulation. The HCC-78 xenograft thus serves as a critical translational tool for evaluating novel therapeutic strategies in ROS1 fusion-positive NSCLC, enabling robust pharmacodynamic profiling, tumor growth inhibition studies, and biomarker-driven endpoint analyses in a controlled preclinical setting.

Cell Line Information: HCC-78

The HCC-78 cell line is a well-characterized human NSCLC model with established genetic, phenotypic, and growth characteristics. The following table summarizes the essential cell line parameters relevant to xenograft model development and preclinical application.

Our Services

Alfa Cytology leverages its extensive expertise in NSCLC xenograft model development to deliver the HCC-78 platform as a fully validated, ready-to-deploy preclinical service. Our team ensures rigorous cell line authentication, optimized inoculation protocols, and standardized tumor monitoring workflows to generate high-quality pharmacological data for ROS1 inhibitor programs, combination therapy studies, and biomarker validation projects. Whether your objective is single-agent efficacy screening, resistance modeling, or pharmacodynamic endpoint analysis, Alfa Cytology provides the technical infrastructure and scientific rigor required to advance your compound from preclinical validation toward IND-enabling studies.

Workflow of HCC-78 Xenograft Model Construction

The construction of the HCC-78 xenograft model follows a standardized, multi-step workflow designed to ensure reproducible tumor growth, molecular fidelity, and robust pharmacological readouts. Each phase is executed under strict quality control measures to maintain consistency across studies and to generate reliable preclinical data for ROS1-targeted therapeutic evaluation.

1. Cell Line Preparation and Authentication: HCC-78 cells are recovered from cryogenic storage and expanded under adherent culture conditions in RPMI 1640 supplemented with 10% FBS. Prior to inoculation, cell identity is verified by STR profiling according to ANSI/ATCC ASN-0002.1-2021 standards, and mycoplasma contamination is ruled out by PCR assay. Cells are harvested at 70–80% confluence using trypsin/EDTA or Accutase, washed, and resuspended in serum-free medium or Matrigel for inoculation.
2. Animal Model Selection and Acclimation: Immunocompromised host strains—typically athymic nude mice (Foxn1nu/foxn1nu) or NOD/SCID gamma (NSG) mice—are selected based on study objectives and tumor growth kinetics. Animals are acclimated for 5–7 days under controlled environmental conditions (22±2°C, 50–60% humidity, 12-hour light/dark cycle) with ad libitum access to sterilized food and water. Health status is monitored daily during the acclimation period.
3. Subcutaneous Tumor Inoculation: HCC-78 cells are inoculated subcutaneously into the right flank at a density of 5×10⁶ to 1×10⁷ cells per mouse in a 100–200 µL suspension, typically mixed 1:1 with Matrigel to enhance initial tumor take rates. Inoculation is performed under aseptic conditions using a 25-gauge needle. Tumor formation is monitored by palpation beginning 3–5 days post-inoculation.
4. Tumor Growth Monitoring and Randomization: Tumor dimensions are measured twice weekly using digital calipers, and tumor volume is calculated via the modified ellipsoid formula (V = 0.5 × length × width²). Once tumors reach a mean volume of 100–150 mm³, animals are randomized into treatment and control groups (n≥8 per group) to ensure balanced baseline tumor volumes and body weights across cohorts.
5. Therapeutic Intervention and Dosing: Test compounds are administered according to predefined dosing schedules (e.g., oral gavage, intraperitoneal, or intravenous injection) with vehicle controls run in parallel. Dosing regimens, including dose levels, frequency, and duration, are customized based on compound pharmacokinetics and study objectives. Body weights and clinical signs are recorded throughout the dosing period to assess tolerability.
6. Endpoint Analysis and Sample Collection: Studies are terminated when control tumors reach institutional endpoint criteria (typically 1,500–2,000 mm³ or 10% body weight loss). At necropsy, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E, IHC for ROS1, Ki-67, cleaved caspase-3), biomarker analysis (phospho-ROS1, phospho-ERK, phospho-AKT by Western blot), and pharmacokinetic sampling. Tumor growth inhibition (TGI) is calculated as the primary efficacy endpoint.
7. Data Analysis and Reporting: Tumor growth curves, body weight trajectories, and survival data are analyzed using appropriate statistical methods. Pharmacodynamic biomarkers are quantified and correlated with tumor response. A comprehensive study report is generated, including methodology, raw data, statistical analyses, and interpretive summaries to support regulatory filings and internal decision-making.

Fig 2. HCC-78 xenograft model construction workflow.

Case Study-HCC-78 Xenograft Model Development

In a representative preclinical engagement, the HCC-78 xenograft model was employed to evaluate the efficacy of a next-generation ROS1 inhibitor in comparison with standard-of-care crizotinib. Following subcutaneous inoculation of authenticated HCC-78 cells into athymic nude mice, tumors were established and randomized into vehicle, crizotinib, and investigational compound cohorts. The investigational agent demonstrated dose-dependent tumor growth inhibition with superior pharmacodynamic suppression of phospho-ROS1 and downstream phospho-ERK signaling relative to the reference standard. Additionally, the study incorporated a resistance arm in which HCC-78 cells with acquired resistance to the investigational compound were generated through long-term in vitro exposure, and the resulting resistant population was subsequently evaluated in vivo to identify bypass mechanisms involving EGFR and KRAS pathway activation. These findings provided critical preclinical validation for the compound's mechanism of action and informed the design of subsequent combination therapy strategies targeting emergent resistance pathways, supporting the advancement of the program toward IND-enabling toxicology studies.

Why Choose Alfa Cytology?

Alfa Cytology combines deep scientific expertise in NSCLC biology with rigorous operational standards to deliver HCC-78 xenograft model services that meet the highest preclinical research expectations. Our integrated approach ensures data integrity, study flexibility, and seamless project execution from model initiation through final reporting.

• Authenticated, mycoplasma-free HCC-78 cell banks with verified STR profiles and documented ROS1 fusion/TP53 mutation status ensure molecular fidelity across all studies.
• Standardized xenograft protocols with optimized cell inoculation densities, Matrigel formulations, and host strain selection deliver reproducible tumor take rates and growth kinetics.
• Comprehensive pharmacodynamic and biomarker analysis capabilities, including IHC, Western blot, and multiplex profiling, enable mechanism-of-action validation and resistance pathway characterization.
• Flexible study designs accommodating single-agent efficacy, combination therapy, dose-response, and resistance modeling to align with diverse preclinical development objectives.
• Robust quality control and data management systems with real-time tumor monitoring, statistical analysis, and regulatory-compliant reporting support IND-enabling decision-making.
• Dedicated project management and scientific consultation throughout the study lifecycle, ensuring transparent communication, milestone adherence, and actionable data interpretation.

Contact Us

Accelerate your ROS1-targeted therapeutic program with Alfa Cytology's validated HCC-78 xenograft model service. Reach out to our scientific team today to discuss your study requirements, review customized protocol options, and receive a detailed project proposal tailored to your preclinical development timeline. Contact us now to initiate your next-generation NSCLC drug evaluation with confidence and precision.

For research use only. Not intended for any clinical use.